The company ditches lorigerlimab in prostate cancer.
ApexOnco Front Page
Recent articles
But the Day One deal is still 29% below where the shares stood at the start of this year.
New listings reveal expanded phase 3 programmes for J&J’s Talvey and Amgen’s tarlatamab.
Opdivo plus Yervoy scores a remarkable survival benefit in Checkmate-8HW, whose control arm presents some comparability difficulties.
The first-line liver cancer Emerald-1 trial is positive, but only up to a point.
Skyscraper-08 yields a positive result that – with caveats – looks decent on a cross-trial basis too.
Bristol renews its focus on chronic lymphocytic leukaemia, but rivals haven’t fared so well here.
Three years after licensing in the IAP inhibitor xevinapant Merck KGaA will find out if the deal was worth it.